Outstanding Poster Presentation Awards
About the Award
The top poster presentations from each of the three poster sessions that occur during the ASGCT Annual Meeting are awarded Outstanding Poster Presentation Awards. Awardees are honored through notification to all meeting attendees and receive a special certificate for their contributions
Criteria and Selection
Any ASGCT member or associate member who submits an abstract to the Annual Meeting is eligible to receive the award. For more information, review the abstract submission guidelines coming soon.
Past Recipients
2022
Juan Aponte-Ubillus
Bioprocess Strategies to Mitigate the Impact of Proteases on Adeno-Associated Viral (AAV) Vector VP1 Capsid Content
Motahareh Arjomandnejad
Tropism of AAV-rh32.33 for Skin Endothelial Cells and Fibroblasts
Matthew Burke
Comprehensive Evaluation of the Fiber Type and Fiber Size Preference of AAV8 and AAV9 in the Canine DMD Model
Jacob Bridge
Efficient Non-Viral Engineering and Large-Scale Expansion of Polyclonal γδ T Cells
Dylan Cable
Cell Type-Specific Differential Expression in Spatial Transcriptomics for Identification of Pathologically-Relevant Genetic Targets
Hao Chang
Tri-GalNAc Conjugation to AAV Capsid Enhances Transduction of Human Hepatocytes In Vitro
Kristina Chern
Evaluation of rAAV Serotypes in the Murine Anterior Chamber for the Treatment of Glaucoma
Miguel Chuapoco
Intravenous Gene Transfer Throughout the Brain of Infant Old World Primates Using AAV
Cristina Colleoni
Characterization of the Non-Cell Autonomous Effects of Oncogene Activation on Hematopoiesis as a Possible Adverse Event in HSC Gene Therapy
Colin Cook
AAV Superproduction: Achieving 1016vg/L Productivity in the High Density Cell Respirator
Jérôme Denard
AAV-Mediated Gene Therapy of Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME) and Farber Disease
Zac Elmore
AAV Hijacks Cellular Secretion Machinery for Efficient Viral Egress
Ryan Fink
Novel RNA Therapeutic Strategy to Optimize RNA Targeting in Brain Cancer
Anna Hartley
Identification of an Antiviral Drug as a Novel Potentiator of H-1PV-Mediated Oncolysis
Juliette Hordeaux
Determining the Minimum Effective Dose (MED) of a Clinical Candidate AAV Vector Encoding Engineered Alpha-Galactosidase A Transgene in a Mouse Model of Fabry Disease
Ram Jha
Development of a Minocycline Mediated Protein-Protein Displacement Platform Using an Anti-Minocycline Single Domain Antibody and a Dedicated Displaceable Peptide
Seonah Kang
Adaptation of Multi-Plasmid Transfection-Based AAV Production to High Density Cell Respirator Bioreactors Yields Functional Vector
Erin Kavanaugh
Nanoparticles for Correction of a Rare Cystic Fibrosis Variant
Takashi Kishimoto
Combination of ImmTOR Tolerogenic Nanoparticles and IL-2 Mutein Synergistically Inhibits the Formation of Anti-AAV Antibodies
Myungeun Lee
A Novel Chimeric Nanosystem for Piggyback Delivery of mRNA Vectors
Anoushka Lotun
Ubiquitous ASPA Gene Therapy Changes Neuronal Cell Expression in Region-Specific Manner in Canavan Disease
Christopher Luthers
Quantification of DNA Contamination within Recombinant Adeno Associated Virus Preps Correlates with CD34+ Cell Potential
Oriana Mandolfo
Developing an iPSC-Based Therapeutic Approach to Reverse MPS IIIA Neurodegeneration
Sean McCutcheon
CRISPR-Based Epigenome Editing Screens in Primary Human T Cells
Christopher Nicolai
VivoVec: A Novel Lentiviral-Based In Vivo CAR T Cell Generation Platform with Viral Particle Surface Engineering Incorporating T Cell Activating and Co-Stimulatory Ligands
Julia Peterson
A Protocol for Expanding Mouse HSPCs to High Cell Yields for Pre-Clinical Screenings of Gene Therapy Vector Constructs
Francesco Puzzo
R-Loops as Determinant of AAV Integration by Homologous Recombination
Ziqing Qian
Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides
Matthew Roach
Identification and Validation of Target Receptors for AAV9
Joan Roag-Soriano
AAV-Mediated Expression of αKlotho Isoforms Rescues Relevant Aging Hallmarks in SAMP8 Mice
Anna Sternberg
An Enhanced Hemostatic Factor VIII Variant for Hemophilia A Gene Therapy
Amber Van Laar
Safety and Preliminary Clinical Findings of Neurosurgical AAV2-GDNF Delivery for Parkinson’s Disease
Anne Vonada
Correction of Phenylketonuria by Drug-Mediated Expansion of Transplanted Hepatocytes In Vivo
Jennifer Waldo
Split dCas9 AAV for Knockdown of HTT
Carlos Munoz Zuluga
Identification of the Therapeutically Beneficial Intravenous Dose of AAVrh.10hFXN to Treat the Cardiac Manifestations of Friederichs's Ataxia
2021
Marco Alessandrini
Development of Anti-CD19 Chimeric Antigen Receptor T-Cells with Immune Checkpoint Silencing
Robyn Bell
Assessment of F/HN Pseudotyped Lentiviral Vector Following Intravenous Delivery to Mice
Máté Borsos
Simultaneous Detection of AAV Genome, Transcript, and Protein Localization in Intact Cells and Tissues at High Resolution
Qian Chen
AAV9 Capsid-Anti-AAV9 Antibody Immune Complexes Promote Complement Activation and Cytokine Release In Vitro
Beatrice Cianciotti
LAG-3, Tim-3 or 2B4 Disruption Differentially Regulate the Anti-Tumor Response of TCR Gene-Edited Human Memory Stem T Cells
Agnieszka Czechowicz
Gene Therapy for Fanconi Anemia [Group A]: Preliminary Results of Ongoing RP-L102 Clinical Trials
Brianna Davey
Anti-CAR Antibody Detected after Infusion of Autologous CD4-MBL-CAR/CXCR5 CAR T Cells in SIV-Infected Rhesus Macaques
Michael Florea
High Efficiency Purification of Multiple AAV Serotypes Using AAVX Column Chromatography
Courtney Garrett
Treatment of Feline GM1 Gangliosidosis by Cerebrospinal Fluid Delivery of AAV9 or AAVrh10
Daniel Gibbs
Novel RNA-Targeting Gene Therapy Approach for Usher’s Syndrome Type II Retinitis Pigmentosa
Veronica Gough
Adenine Base Editing to Modulate mRNA Splicing as a Therapeutic Strategy for Duchenne Muscular Dystrophy
Firas Hamdan
Synergestic Tumor-Killing Effect by Cross-Hybrid IgGA Fc
Jenna Harris
Enabling Targeted Cargo Delivery to Hematopoietic Stem and Progenitor Cells with Biomimetic Nanoparticles
Dane Hazelbaker
Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia
Claudia Juarez-Molina
Gene Therapy for Autoimmune Pulmonary Alveolar Proteinosis
Sushrut Kamerkar
Engineered Exosomes Efficiently Deliver STAT6 Antisense Oligonucleotides to Tumor Associated Macrophages (TAMs) Resulting in Potent Local and Systemic Anti-Tumor Activity
Jeong-A Lim
AAV-Mediated Gene Therapy Using a Novel Dual Promoter Prevents Pullulanase-Induced Cytotoxic T Lymphocyte Response and Corrects Major Affected Tissues in GSD IIIa Mice
Anne Maguire
Intravenous AAV Gene Therapy Improves Pre- and Post-Mortem Outcomes in a Feline Model of Sandhoff Disease
Ana Moreno
Long-Lasting Analgesia via Targeted In Situ Repression of Nav1.7
Christopher Nguyen
Expression of AAV Rep78 and Rep52 from Distal Baculovirus loci for Production of Gene Therapy Vectors: Proof-of-Concept and Initial Optimization
Jennifer Noel
Rod-Derived Cone Viability Factor Provides Trophic Support for Cone Photoreceptors in a Pig Model of Retinitis Pigmentosa
Yijia Pan
Temporal Gene Regulation of T Cell Enhancers by Locus Targeted Engineering Enables Cytokine Autonomy and Augments Anti-Tumor Efficacy of iPSC Derived Off-the-Shelf CAR-T Therapy
Angela Papalamprou
Directing Stepwise iPSC MSC Differentiation into iTenocytes Using Combined Transcription Factor Overexpression and Cyclic Loading in 2D Bioreactor
Adrian Pickar-Oliver
Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration
Françoise Piguet
Intravenous Gene Therapy Apporach for Metachromatic Leukodystrophy
Maximillian Richter
P-BCMA-ALLO1 — A Fully Allogeneic Stem Cell Memory T Cell (T<sub>SCM</sub>) CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor Activity
Federico Rossari
Tumor Macrophage-Mediated Cytokine Gene Delivery Improves Trafficking and Anti-Tumor Activity of CAR T Cells against Glioblastoma
Krystal Sandza
Ultra-Sensitive AAV Capsid Detection by Immunocapture-Based Quantitative Polymerase Chain Reaction Following Factor VIII Gene Transfer
Pauline Schmit
High Throughput Phenotype-to-Phylogeny Mapping Identifies AAV Capsid Residues Involved in Neutralization by Human Sera
Nina Timberlake
Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning
Jennifer Waldo
Use of a Split AAV Delivery Platform for the Evaluation of dxCas9 for Allele-Specific Silencing in Huntington’s Disease
Eric Walton
A CRISPRa Screen Identifies Transcription Factors That Can Silence or Activate rAAV Genomes
Adrian Westhaus
AAV Capsid Development in Primary Human Retinal Explants